Russian COVID-19 vaccine, 'Sputnik-V' which has been launched in Russia, may soon become the first official vaccine to be launched in India if clearances are granted. For this, GV Prasad-led Dr Reddy's Laboratories has signed a pact with Russia's sovereign wealth fund Russian Direct Investment Fund (RDIF) to manufacture around 10 crore vaccines in India. Both have been planning to roll out the vaccine in India as early as November. RDIF CEO Kirill Dmitriev spoke to India Today TV about the plans for the launch of vaccine in India. Watch this exclusive interview to know more.Also Read: Russian coronavirus vaccine: 1 in 7 volunteers report side-effects

Russian COVID-19 vaccine: Volunteers would receive a second shot of the Russian COVID-19 vaccine within 21 days of the first shot. The adenovirus-based viral vector vaccine is yet to complete a large-scale clinical trial but has been approved by the Russian government

Dr Reddy's Laboratories stock touched an all-time high of Rs 5,302 today rising 9.87% against previous close of Rs 4,826 on BSE

Kirill Dmitriev, CEO of Russia's sovereign wealth fund Russian Direct Investment Fund, says India will play a vital role in fighting Covid-19 and that government's Make in India initiative has made pharma sector stronger

As part of the settlement, Celgene has agreed to provide Dr Reddy's with a licence to sell volume-limited amounts of generic lenalidomide capsules in the US after March 2022 subject to regulatory approval

Dr Reddy's Laboratories stock which closed 4.24% higher in the previous session gained 4.21% or Rs 195 to close at Rs 4,826 on BSE today

Premium bicycle maker Scott Sports India on Wednesday introduced a full suspension cross country bicycle Spark RC 900 at a whopping Rs 3.7 lakh; Software engineers, physicians, teachers, accountants, analysts, among others are the professionals  who saw the biggest loss of jobs among salaried employees due to coronavirus lockdown; Hyderabad-based Dr Reddy's Laboratories (Dr Reddy's) and Russia's sovereign wealth fund Russian Direct Investment Fund (RDIF) have joined hands to carry out clinical trials and distribution of 100 million doses of coronavirus vaccine Sputnik V in India. Watch this and more on News Blast.Also Read: 33% Delhiites exposed to coronavirus, have Covid antibodies, reveals latest sero survey

COVID-19 vaccine from Russia! Dr Reddy's ties up with a Russian firm for 100 million dosesHyderabad-based Dr Reddy's Laboratories (Dr Reddy's) and Russia's sovereign wealth fund Russian Direct Investment Fund (RDIF) have joined hands to carry out clinical trials and distribution of 100 million doses of coronavirus vaccine Sputnik V in India. Sputnik V vaccine is undergoing final stage clinical trials in Russia. It is also being tested in several other countries. \"Deliveries could potentially...

Deliveries could potentially begin in late 2020 subject to completion of successful trials and registration of the vaccine by regulatory authorities in India, a joint statement issued by RDIF and Dr Reddy's says

Dr Reddy's Lab share touched an intraday high of Rs 4651.95, a rise of 4.7% on BSE

The Sputnik V vaccine, developed by the Gamaleya research institute in coordination with the Russian defence ministry, is the world's first registered vaccine against COVID-19 based on the human adenoviral vectors platform

Coronavirus vaccine trials: While China has four vaccine candidates in third or final stages of clinical trials, there are at least two companies from the United States and one from UK and Germany, which are planning to rollout vaccine before December, if everything goes as per the plan

China launched a vaccine emergency use programme in July, offering three experimental shots developed by a unit of state pharmaceutical giant China National Pharmaceutical Group (Sinopharm) and U.S.-listed Sinovac Biotech

The head of the world's largest vaccine manufacturer said that the world will need 15 billion doses of the COVID-19 shot if it is a two-dose vaccine

DCGI VG Somani in his order also asked Serum Institute to suspend any new recruitment in Phase 2 and 3 clinical trials until further notice; SII also need to increase safety monitoring of test subjects vaccinated under trials so far

Another leading candidate for coronavirus vaccine is Moderna. The company said that it is talking to multiple countries for the rollout of the COVID-19 vaccine.

AstraZeneca CEO Pascal Soriot said that the decision to resume the coronavirus vaccine trials rests with a group of independent experts who are working to understand if the volunteer's condition was coincidental or a result of the inoculation

AstraZeneca on Wednesday \"voluntarily\" paused the phase 3 clinical trials after a volunteer developed an \"unexplained\" illness; in India, Serum Institute, one of the partners of University of Oxford, also decided to pause the trials following the DCGI notice

Phase 2/3 COVID-19 vaccine trials being conducted across 17 sites in India paused till further instructions from regulator; could delay vaccine development process as Serum Institute is front-runner when it comes to companies producing COVID-19 vaccines in India

Serum has also started manufacturing the vaccine, targeting to use in India and 92 other countries upon completion of trials and regulatory clearances